Experts who took part in Patient-Centered Oncology Care® 2021 said when guidelines recommend high-cost targeted therapies or immunotherapies, the focus must turn to areas such as imaging, diagnostic tests, and other elements that contribute to the cost of care.
With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.
Having the option of receiving care in their community instead of a large hospital located hours away is not only a benefit for many patients, but research is showing community oncology practices are a low-cost, high-quality provider of care, explained Jeff Patton, MD, executive chairman of Tennessee Oncology and CEO of OneOncology.
Davey Daniel, MD, an oncologist with Tennessee Oncology in Chattanooga, spoke with The American Journal of Managed Care® (AJMC®) about the withdrawal of indications in small cell lung cancer (SCLC) for the PD-1 inhibitors pembrolizumab and nivolumab.
Davey Daniel, MD, hematology/medical oncology specialist, Tennessee Oncology, discusses findings of an abstract presented at ASCO 2021 showing a lower total cost of care paid by Medicare for episodes of care for patients in the Oncology Care Model (OCM) enrolled in clinical trials vs those receiving routine care.
Edward Licitra, MD, PhD, medical oncologist, Astera Health Partners, discusses his thoughts on what value-based cancer care entails and how physicians can best align their goals with those of the patient and health plan.
Jeff Patton, MD, CEO, OneOncology, and chairman of the board, Tennessee Oncology, discusses what influence COVID-19 will have on discussions at the Community Oncology Conference 2021, as well as takeaways he hopes audience members and participants gain from the conference.